netFormulary Chelsea and Westminster Hospital NHS
NHS Foundation Trust  
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
08.01.05  Expand sub section  Other antineoplastic drugs
08.01.05  Expand sub section  Amsacrine
08.01.05  Expand sub section  Arsenic trioxide
08.01.05  Expand sub section  Bevacizumab
08.01.05  Expand sub section  Bexarotene to top
08.01.05  Expand sub section  Bortezomib
08.01.05  Expand sub section  Brentuximab vedotin
08.01.05  Expand sub section  Cetuximab
08.01.05  Expand sub section  Crisantaspase
08.01.05  Expand sub section  Dacarbazine and Temozolomide to top
08.01.05  Expand sub section  Erlotinib
08.01.05  Expand sub section  Hydroxycarbamide
08.01.05  Expand sub section  Imatinab
08.01.05  Expand sub section  Ipilimumab
08.01.05  Expand sub section  Mitotane to top
08.01.05  Expand sub section  Panitumumab
08.01.05  Expand sub section  Pentostatin
08.01.05  Expand sub section  Platinum compounds
08.01.05  Expand sub section  Porfimer sodium and temoporfin
08.01.05  Expand sub section  Procarbazine to top
08.01.05  Expand sub section  Protein kinase inhibitors
Cytotoxic Drug Abemaclib ( Verzenios®)
View adult BNF View childrens BNF
Formulary
On Formulary
High Cost Medicine

Abemaclib (Verzenios®) 50mg film coated tablets

Abemaclib (Verzenios®) 100mg film coated tablets

Abemaclib (Verzenios®) 150mg film coated tablets

For use in line with NICE TA563: Abemaciclib with an aromatase inhibitor for previously, untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer

 
   
Afatinib (Giotrif®)
View adult BNF View childrens BNF
Formulary
On Formulary
High Cost Medicine
Afatinib (Giotrif®) 20mg tablet
Afatinib (Giotrif®) 30mg tablet
Afatinib (Giotrif®) 40mg tablet
Afatinib (Giotrif®) 50mg tablet
For use in line with NICE TA310 (Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer)
 
Link  NICE TA310: Lung cancer (non small cell, EGFR mutation positive) - afatinib
   
Alectinib (Alecensa®)
View adult BNF View childrens BNF
Formulary
On Formulary

Alectinib (Alecensa®) 150mg capsules

 

For use in line with NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer

 
   
Cytotoxic Drug Binimetinib (Mektovi®)
View adult BNF View childrens BNF
Formulary
NICE Formulary
High Cost Medicine
NHS England

Binimetinib (Mektovi) 15 mg film-coated tablets

 

In line with NICE TA562L Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma

 
   
Cytotoxic Drug Brigatinib (Alunbrig®)
View adult BNF View childrens BNF
Formulary
On Formulary
High Cost Medicine

Brigatinib (Alunbrig®) 30mg film coated tablets

Brigatinib (Alunbrig®) 90mg film coated tablets

Brigatinib (Alunbrig®) 180mg film coated tablets

For use in line with NICE TA 571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib

 
   
Cytotoxic Drug Cabozantinib (Cometriq®)
View adult BNF View childrens BNF
Formulary
NICE Approved
High Cost Medicine
Cancer Drugs Fund
Cabozantinib
For use in line with NICE TA463 (Cabozantinib for previously treated advanced renal cell carcinoma) 
   
Crizotinib (Xalkori®)
View adult BNF View childrens BNF
Formulary
NICE Formulary
High Cost Medicine
Cancer Drugs Fund

Crizotinib (Xalkori®) 200mg capsule
Crizotinib (Xalkori®) 250mg capsule
For use in line with NICE TA406 (Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer)
For use in line with NICE TA422 (Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer)

For use in line with NICE TA529 (Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer)

 
Link  NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Link  NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
   
Dasatinib (Sprycel®)
View adult BNF View childrens BNF
Formulary
NICE Formulary
High Cost Medicine
Cancer Drugs Fund
Dasatinib (Sprycel®) 20mg tablet
Dasatinib (Sprycel®) 50mg tablet
Dasatinib (Sprycel®) 70mg tablet
Dasatinib (Sprycel®) 100mg tablet
For use in line with NICE TA241 (Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML) (part review of NICE technology appraisal guidance 70), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance)

For use in line with NICE TA251 (Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia)
For use in line with NICE TA425 (Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia)
For use in line with NICE TA426 (Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia)

 
Link  NICE TA241: CML for whom treatment with imatinib has failed because of intolerance
Link  NICE TA251: Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
   
Cytotoxic Drug Encorafenib (Braftovi®)
View adult BNF View childrens BNF
Formulary
NICE Formulary
High Cost Medicine
NHS England

Encorafenib (Braftovi) 50 mg hard capsules

Encorafenib (Braftovi) 75 mg hard capsules

In line with NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma

 
   
Erlotinib (Tarceva®)
View adult BNF View childrens BNF
Formulary
NICE Formulary
Erlotinib (Tarceva®) 25mg tablet
Erlotinib (Tarceva®) 100mg tablet
Erlotinib (Tarceva®) 150mg tablet
For use in line with NICE TA374 (Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy)
For use in line with NICE TA227 (Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer)
For use line with NICE TA256 (Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation)
 
Link  NICE TA227: Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer
Link  NICE TA256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation
Link  NICE TA374 Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
   
Everolimus (Votubia®)
View adult BNF View childrens BNF
Formulary
NICE Formulary
High Cost Medicine
Everolimus (Votubia®) 2.5mg tablet
Everolimus (Votubia®) 5mg tablet
Everolimus (Votubia®) 10mg tablet
For use in line with NICE TA348 (Everolimus for preventing organ rejection in liver transplantation)
For use in line with NICE TA421 (Everolimus with exemestane for treating advanced breast cancer after endocrine therapy)
For use in line with NICE TA449 (Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease)
 
Link  NICE TA348: Everolimus for preventing organ rejection in liver transplantation
Link  NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Link  NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
   
Gefitinib (Iressa®)
View adult BNF View childrens BNF
Formulary
NICE Formulary
High Cost Medicine
Gefitinib (Iressa®) 250mg tablet
For use in line with NICE TA374 (Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy)
For use in line with NICE TA192 (Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer)  
Link  NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib
Link  NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
   
Cytotoxic Drug Imatinib (Gilvec®)
View adult BNF View childrens BNF
Formulary
NICE Formulary
High Cost Medicine
Imatinib (Gilvec®) 100mg tablet
Imatinib (Gilvec®) 400mg tablet
For use in line with NICE TA70 (Guidance on the use of imatinib for chronic myeloid leuakaemia)
For use in line with NICE TA209 (Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours)
For use in line with NICE TA (Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML) (part review of NICE technology appraisal guidance 70), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance)
For ues in line with NICE TA (Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia)
For use in line with NICE TA326 (Imatinib for the adjuvant treatment of gastrointestinal stromal tumours)
For us in line with NICE TA86 (Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours)
For use in line with NICE TA425 (Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia)
For use in line with NICE TA426 (Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia)
 
Link  NICE TA209: Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib
Link  NICE TA241: Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant)
Link  NICE TA251: Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib
Link  NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Link  NICE TA70: Leukaemia (chronic myeloid) - imatinib
Link  NICE TA86: Gastro-intestinal stromal tumours (GIST) - imatinib
   
Lapatinib (Tyverb®)
View adult BNF View childrens BNF
Formulary
NICE Formulary
High Cost Medicine
Lapatinib (Tyverb®) 250mg tablet
For use in line with NICE TA257(Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2)
 
Link  NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
   
Nilotinib (Tasigna®)
View adult BNF View childrens BNF
Formulary
NICE Formulary
High Cost Medicine
Nilotinib (Tasigna®) 200mg capsule
For use in line with NICE TA241 (Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML) (part review of NICE technology appraisal guidance 70), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance)
For use in line with NICE TA251 (Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia)
For use in line with NICE TA425 (Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia)
For use in line with NICE TA426 (Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia)
 
Link  NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML
Link  NICE TA251: Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
   
Pazopanib (Votrient®)
View adult BNF View childrens BNF
Formulary
NICE Formulary
High Cost Medicine
Pazopanib (Votrient®) 200mg tablet
Pazopanib (Votrient®) 400mg tablet
For use in line with NICE TA215 (Pazopanib for the first-line treatment of advanced renal cell carcinoma)
 
Link  NICE TA215: Pazopanib for the first-line treatment of advanced renal cell carcinoma
   
Sunitinib
View adult BNF View childrens BNF
Formulary
On Formulary
High Cost Medicine
Cancer Drugs Fund

Sunitinib (Sutent®) 12.5mg capsule
Sunitinib (Sutent®) 25mg capsule

Sunitinib 37.5 mg capsules

Sunitinib 50 mg capsules

 
Link  NICE TA169: Renal cell carcinoma - sunitinib
Link  NICE TA178: Renal cell carcinoma
Link  NICE TA179: Gastrointestinal stromal tumours - sunitinib
   
Cytotoxic Drug Temsirolimus (Torisel®)
View adult BNF View childrens BNF
Formulary
On Formulary
High Cost Medicine
Cancer Drugs Fund
Temsirolimus (Torisel®) 30mg infusion 
Link  NICE TA178: temsirolimus for first-line treatment of advanced and/or metastatic renal cell carcinoma
Link  NICE TA207: Mantle cell lymphoma (relapsed) - temsirolimus (terminated appraisal)
   
Vemurafenib (Zelboraf®)
View adult BNF View childrens BNF
Formulary
NICE Formulary
High Cost Medicine
Vemurafenib (Zelboraf®)240mg tablet
For use in line with NICE TA269 (Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma)  
Link  NICE TA269: Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib
   
08.01.05  Expand sub section  Taxanes
08.01.05  Expand sub section  Topoisomerase I inhibitors
08.01.05  Expand sub section  Trabectedin
08.01.05  Expand sub section  Trastuzumab to top
08.01.05  Expand sub section  Tretinoin
08.01.05  Expand sub section  Vismodegib
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

On Formulary

Formulary  

NICE Formulary

Nice Approved / Formulary  

NICE Approved

NICE approved  

Amber Restricted

Amber Restricted Use  

Non Formulary

Non Formulary  

netFormulary